Clinical trial NCT03110198: Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis
Official title: A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Ulcerative Colitis, Unspecified
Keywords: Mesalazine
Ulcerative Colitis(UC)
Enema
Lead sponsor: Xijing Hospital of Digestive Diseases
Sponsor class: OTHER
Collaborators: name: Shanghai Tongji Hospital, Tongji University School of Medicine
name: First Affiliated Hospital of Zhongshan Medical University
First posted: 2017-04-12
Enrollment: 528
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The research aims to evaluate the efficacy and safety of that mesalazine with hydrocortisone sodium succinate for the induction of clinical remission during a 4-week double-blind treatment period in active UC (define as total Mayo score of greater than or equal to 4 and less than or equal to 10). A total of 528 patients will be randomly divided into three group, one will receive mesalazine 4g with hydrocortisone sodium succinate 100mg enema, and the other two group will respectively to receive mesalazine 4g and hydrocortisone sodium 100mg one times daily for 4 weeks. The end of the study for every patient is the improvement of main symptoms.The primary endpoint is the clinical remission after 2 and 4 weeks double-blind treatment, defined on the basis of a total Mayo score ≤ 2 points, with no subscore \> 1 point. The secondary endpoint are endoscopic mucosal healing at week 2 and 4 of double-blind period, defined as an absolute subscore for endoscopy portion of the Mayo score of 0 point and the change from baseline in Quality of Life at week 4 of double-blind period based on the IBDQ.


Eligibility criteria: Inclusion Criteria:

1. Male or female Chinese patients aged ≥18 to ≤ 70 years
2. Newly diagnosed or recurrent active ulcerative colitis (A gold standard for the diagnosis of ulcerative colitis is not available. The diagnosis should be established by a combination of medical history, clinical evaluation, and typical endoscopic and histological findings. An infective cause should be excluded. Where there is doubt about the diagnosis, endoscopic and histological confirmation is necessary after an interval.)
3. Extent of colonic involvement and endoscopy subscore of Mayo score as confirmed by colonoscopy (it should be done within 15 days prior to randomization)
4. Total Mayo score of at least 4 and a score of ≥ 2 for colonoscopy
5. Oralthe stability dose of 5-ASA medicine 14days.
6. Negative stool test at screening to rule out parasites and bacterial pathogens
7. The patient is compliant with Patient Daily Diary
8. Women with childbearing potential must have an efficacious contraception as judged by the investigators and must have a negative pregnancy test result at screening
9. Signed Informed Consent obtained before any trial-related procedures.

Exclusion Criteria:

1. Severe/fulminant ulcerative colitis or toxic dilatation of the colon
2. Prior bowel resection surgery
3. Known infection of human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV) (Note active Hepatitis B patients should be excluded from the study e.g. HBeAg positive or HBV DNA positive, with the exception for inactive HBsAg carrier)
4. Take the following treatment:

   1. Any 5-ASA enema or suppository therapy during the 14 days prior to screening
   2. Corticosteroids (oral, intravenous, intramuscular, or rectal ) within 7 days prior to screening
   3. Any immunomodulating/suppressive agents during the 60 days prior to screening
   4. Any Anti-TNF therapy during the 6 months prior to screening
   5. Antibiotics (metronidazole and ciprofloxacin) within 7 days prior to screening
   6. Loperamide, nicotine patch and mucilages within 7 days prior to screening
   7. Traditional Chinese Medicine for the treatment of UC (any pharmaceutical form) within 7 days prior to screening
5. Patients allergic to 5-ASA and derivative, any of the excipients, aspirin, or salicylates
6. Known significant hepatic function abnormalities, defined as the values of serum ALT or AST are equal to or more than twice of the upper limit of normal value
7. Women who are planning or actual pregnancy or lactation during study period
8. Alcohol addiction (\>40 g of alcohol/day equivalent to \>1 L of beer/day, 0.5 L of wine/day, or 6 glasses (2 centiliter, cl) of liquor/day)
9. Drug addiction confirmed by patients' medical history
10. History of disease that would interfere with their participation in the trial, including malignant diseases, bleeding disorders, active gastric or active duodenal ulcers, autoimmune diseases, and mental or emotional disorder
11. Patient participating or having participated in another clinical study 30 days prior to screening
12. Patient who are unlikely to comply with the protocol as judged by the investigator
13. Patients who are unable to fill in the Patient Daily Diary or follow data-capturing procedures
14. Patients with one or more of the diseases: bacillary dysentery, amebic dysentery, chronic schistosomiasis, intestinal tuberculosis and Crohn's disease
15. Patients with any other disease or condition which might interfere with study assessment as judged by the investigator.

Primary outcomes:
measure: Change of clinical remission
timeFrame: 2 weeks, 4 weeks
Secondary outcomes:
measure: Change of endoscopic mucosal healing
timeFrame: 2 weeks, 4 weeks
measure: Change of quality of life based on the IBDQ
timeFrame: 2 weeks, 4 weeks
measure: Change of mental health by Anxiety and Depression Assessment Scale
timeFrame: 2 weeks, 4 weeks
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Digestive Disease
state: Shaanxi
Study officials:
affiliation: China,Shaanxi,Xi'an, Xijing Hospital of Digeetive Disease
name: jie Liang, professor
role: PRINCIPAL_INVESTIGATOR
References: